ASPARTYLPROTEASE INHIBITOR AND METHOD OF IDENTIFYING THEREOF

ASPARTYLPROTEASE INHIBITOR AND METHOD OF IDENTIFYING THEREOF

beta -amyloid peptide ( beta AF) production in cell culture and in vivo is inhibited by administering aspartyl protease inhibitors, particularly inhibitors of proteases of cathepsin D. Useful aspartyl protease inhibitors can be selected in a two-step assay, where test compounds are first screened fo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: VARGHESE JOHN, LAGUZZA BENNETT COLEMAN, LITTLE SHEILA PARKS, SINHA SUKANTO, LIEBERBERG IVAN M, DOVEY HARRY F
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator VARGHESE JOHN
LAGUZZA BENNETT COLEMAN
LITTLE SHEILA PARKS
SINHA SUKANTO
LIEBERBERG IVAN M
DOVEY HARRY F
description beta -amyloid peptide ( beta AF) production in cell culture and in vivo is inhibited by administering aspartyl protease inhibitors, particularly inhibitors of proteases of cathepsin D. Useful aspartyl protease inhibitors can be selected in a two-step assay, where test compounds are first screened for aspartyl protease inhibition activity in vitro in noncellular assays. Those test compounds which are found to display protease inhibition activity are then tested in cellular assays for beta AP production inhibition. Those test compounds which are capable of inhibiting intracellular beta -amyloid production may be incorporated in pharmaceutical compositions.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CZ184194A3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CZ184194A3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CZ184194A33</originalsourceid><addsrcrecordid>eNrjZLBxDA5wDAqJ9AkI8g9xdQx2VfD08_B08gzxD1Jw9HNR8HUN8fB3UfB3U_B0cfUL8XSL9PRzVwjxcA1y9XfjYWBNS8wpTuWF0twM8m6uIc4euqkF-fGpxQWJyal5qSXxzlGGFiaGliaOxsaEVQAAjbUpHg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ASPARTYLPROTEASE INHIBITOR AND METHOD OF IDENTIFYING THEREOF</title><source>esp@cenet</source><creator>VARGHESE JOHN ; LAGUZZA BENNETT COLEMAN ; LITTLE SHEILA PARKS ; SINHA SUKANTO ; LIEBERBERG IVAN M ; DOVEY HARRY F</creator><creatorcontrib>VARGHESE JOHN ; LAGUZZA BENNETT COLEMAN ; LITTLE SHEILA PARKS ; SINHA SUKANTO ; LIEBERBERG IVAN M ; DOVEY HARRY F</creatorcontrib><description>beta -amyloid peptide ( beta AF) production in cell culture and in vivo is inhibited by administering aspartyl protease inhibitors, particularly inhibitors of proteases of cathepsin D. Useful aspartyl protease inhibitors can be selected in a two-step assay, where test compounds are first screened for aspartyl protease inhibition activity in vitro in noncellular assays. Those test compounds which are found to display protease inhibition activity are then tested in cellular assays for beta AP production inhibition. Those test compounds which are capable of inhibiting intracellular beta -amyloid production may be incorporated in pharmaceutical compositions.</description><edition>5</edition><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>1995</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19950315&amp;DB=EPODOC&amp;CC=CZ&amp;NR=184194A3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,782,887,25571,76555</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19950315&amp;DB=EPODOC&amp;CC=CZ&amp;NR=184194A3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>VARGHESE JOHN</creatorcontrib><creatorcontrib>LAGUZZA BENNETT COLEMAN</creatorcontrib><creatorcontrib>LITTLE SHEILA PARKS</creatorcontrib><creatorcontrib>SINHA SUKANTO</creatorcontrib><creatorcontrib>LIEBERBERG IVAN M</creatorcontrib><creatorcontrib>DOVEY HARRY F</creatorcontrib><title>ASPARTYLPROTEASE INHIBITOR AND METHOD OF IDENTIFYING THEREOF</title><description>beta -amyloid peptide ( beta AF) production in cell culture and in vivo is inhibited by administering aspartyl protease inhibitors, particularly inhibitors of proteases of cathepsin D. Useful aspartyl protease inhibitors can be selected in a two-step assay, where test compounds are first screened for aspartyl protease inhibition activity in vitro in noncellular assays. Those test compounds which are found to display protease inhibition activity are then tested in cellular assays for beta AP production inhibition. Those test compounds which are capable of inhibiting intracellular beta -amyloid production may be incorporated in pharmaceutical compositions.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1995</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLBxDA5wDAqJ9AkI8g9xdQx2VfD08_B08gzxD1Jw9HNR8HUN8fB3UfB3U_B0cfUL8XSL9PRzVwjxcA1y9XfjYWBNS8wpTuWF0twM8m6uIc4euqkF-fGpxQWJyal5qSXxzlGGFiaGliaOxsaEVQAAjbUpHg</recordid><startdate>19950315</startdate><enddate>19950315</enddate><creator>VARGHESE JOHN</creator><creator>LAGUZZA BENNETT COLEMAN</creator><creator>LITTLE SHEILA PARKS</creator><creator>SINHA SUKANTO</creator><creator>LIEBERBERG IVAN M</creator><creator>DOVEY HARRY F</creator><scope>EVB</scope></search><sort><creationdate>19950315</creationdate><title>ASPARTYLPROTEASE INHIBITOR AND METHOD OF IDENTIFYING THEREOF</title><author>VARGHESE JOHN ; LAGUZZA BENNETT COLEMAN ; LITTLE SHEILA PARKS ; SINHA SUKANTO ; LIEBERBERG IVAN M ; DOVEY HARRY F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CZ184194A33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>1995</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>VARGHESE JOHN</creatorcontrib><creatorcontrib>LAGUZZA BENNETT COLEMAN</creatorcontrib><creatorcontrib>LITTLE SHEILA PARKS</creatorcontrib><creatorcontrib>SINHA SUKANTO</creatorcontrib><creatorcontrib>LIEBERBERG IVAN M</creatorcontrib><creatorcontrib>DOVEY HARRY F</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>VARGHESE JOHN</au><au>LAGUZZA BENNETT COLEMAN</au><au>LITTLE SHEILA PARKS</au><au>SINHA SUKANTO</au><au>LIEBERBERG IVAN M</au><au>DOVEY HARRY F</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ASPARTYLPROTEASE INHIBITOR AND METHOD OF IDENTIFYING THEREOF</title><date>1995-03-15</date><risdate>1995</risdate><abstract>beta -amyloid peptide ( beta AF) production in cell culture and in vivo is inhibited by administering aspartyl protease inhibitors, particularly inhibitors of proteases of cathepsin D. Useful aspartyl protease inhibitors can be selected in a two-step assay, where test compounds are first screened for aspartyl protease inhibition activity in vitro in noncellular assays. Those test compounds which are found to display protease inhibition activity are then tested in cellular assays for beta AP production inhibition. Those test compounds which are capable of inhibiting intracellular beta -amyloid production may be incorporated in pharmaceutical compositions.</abstract><edition>5</edition><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_CZ184194A3
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title ASPARTYLPROTEASE INHIBITOR AND METHOD OF IDENTIFYING THEREOF
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T21%3A45%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=VARGHESE%20JOHN&rft.date=1995-03-15&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECZ184194A3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true